Stay up-to-date with recent developments
HHS announces 15 additional drugs selected for the second cycle of Medicare Drug Price Negotiation Program
Medicare has selected 15 more Medicare Part D drugs to negotiate directly with participating drug companies. In accordance with the IRA, these negotiations will occur in 2025 and any negotiated prices will become effective in 2027.
CMS releases draft guidance for the third cycle of Medicare Drug Price Negotiation Program
On May 12, 2025, CMS issued draft guidance that outlines the requirements for drug manufacturers participating in the negotiation process for 2028 and the effectuation of Maximum Fair Prices (MFPs) in 2026, 2027, and 2028
What you need to know about the Inflation Reduction Act
The Inflation Reduction Act (IRA), which was signed into law in August 2022, is a complex law that contains healthcare reforms, tax changes, and environmental policy provisions that impact several aspects of the U.S. healthcare ecosystem. The IRA aims to address rising healthcare costs by exploring innovative pricing models that seek to prioritize access, value, and quality.
Did you know?
Medicare Drug Price Negotiation Program (MDPNP) pricing goes into effect in 2026
For manufacturers
Valuable insights and support to help you navigate the IRA
The Inflation Reduction Act (IRA) contains implications that pharmaceutical manufacturers need to consider across the full drug discovery, development, and commercialization spectrum. With insights on key elements and a comprehensive understanding of the IRA, our team of experts are here to help you prepare for potential impacts.
Additional resources